Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer.

Ahmad Awada,Sebastian Ochsenreither,Rikke Loevendahl Eefsen,Dirk Arnold,Jeffrey Yachnin,Per Pfeiffer,Christiane Jungels,Richard Greil,Laurids Østergaard Poulsen,Eric Van Cutsem,Lars Thorsson,Christer Svedman,Ignacio García Ribas,Joëlle Collignon

Safety, tolerability and preliminary efficacy of CAN04, a first in class monoclonal antibody against IL1RAP, in combination with nab-paclitaxel and gemcitabine (NG) in subjects with pancreatic cancer.

2021

Ahmad Awada
Sebastian Ochsenreither
Rikke Loevendahl Eefsen
Dirk Arnold
Jeffrey Yachnin
Per Pfeiffer
Christiane Jungels
Richard Greil
Laurids Østergaard Poulsen
Eric Van Cutsem
Lars Thorsson
Christer Svedman
Ignacio García Ribas
Joëlle Collignon

e16228Background: Interleukin-1 Receptor Accessory Protein (IL1RAP) is expressed on cancer and stromal cells in many solid tumors. CAN04 is a fully humanized IgG1 targeting IL1RAP blocking IL-1α an...

Keywords:

Pancreatic cancer
Gemcitabine
safety tolerability
Medicine
Receptor
Stromal cell
Nab-paclitaxel
Cancer research
Cancer
Monoclonal antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations